Open Nav

Please submit your session questions in advance at

Amplyx Pharmaceuticals Inc.

Amplyx was founded on a mission to save lives by developing a new class of antifungal medicine that would overcome the severe limitations of today’s therapeutic options. Amplyx is developing first-in-class products for the treatment of life-threatening infections, with a near-term focus on deadly fungal pathogens in vulnerable, immune-compromised patients. Amplyx's novel small-molecule therapy, APX001, is in clinical development to treat today’s deadliest fungal pathogens, including Candida auris, which the Centers for Disease Control has classified as a “catastrophic threat.” Intravenous and oral formulations of APX001 have been evaluated in a Phase 1 clinical program, with Phase 2 clinical trials in invasive fungal infections currently underway.

  • Date:Monday, February 11
  • Time:10:15 AM - 10:30 AM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23366
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Company update
  • Company
  • Company HQ City:San Diego
  • Company HQ State:California
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:118.5M
  • Size of Last Investment Round:67M
  • Previous and Current Investors:RiverVest Ptrs,NEA,BioMed Ventures,3x5 RiverVest II,Sofinnova Venture,Lundbeckfonden,Arix Bio,Pappas
  • CEO/Top Company Official:Ciara Kennedy, PhD
  • Year Founded:2006
  • Main Therapeutic Focus:Infectious Diseases
  • Lead Product in Development:APX001
  • Development Phase of Primary Product:Phase II
Ciara Kennedy
Amplyx Pharmaceuticals, Inc.